Researchers suggest a strong association between previous abuse of prescription opioids and initiating heroin use. In any case, official statistics shows that over 90 percent people who used heroin reported use of at least one other medication. Higher availability and relatively low cost (compared to prescription opioids) are a few common factors contributing to the increasing use of heroin. Taking rigorous action against drug dealers and educating people about harmful effects of heroin use can help cope with the issue.
Amid the growing opioid crisis in america, the capacity of available therapy programs is falling short of demand. Because of this, individuals needing treatment for dependency on heroin or prescription painkillers have to wait for months, sometimes even years, to get appointments with accredited physicians or to find slots in rehabilitation programs. While waiting to consult with the experts, they are in danger of contracting HIV or hepatitis infections, in addition to dying from a drug overdose.
The country reported maximum opioid misuse among young adults aged 18 to 25, recording an annual incidence of 7.3 percent in the last year. The opioid epidemic has been claiming thousands of lives annually. Additionally, jelqing unintentional opioid poisoning led to approximately 53,000 hospitalizations and 92,262 emergency department (ED) visits throughout the country.
Heroin, specifically, wreak havoc in the previous decades. The CDC reported that a two-time increase in heroin use among young adults aged 18 to 25 in the last ten years. With increased use of the medication, heroin-related overdose deaths also have grown significantly, witnessing a four-fold increase since 2010. Heroin-related overdose death rates saw a 20.6 percent increase between 2014 and 2015, with approximately 13,000 people dying in the exact same in 2015 alone.
To tackle the opioid-related dangers in people awaiting addiction treatment, Dr. Stacey Sigmon and her colleagues at the University of Vermont’s College of Medicine have produced a new therapeutic strategy. They’ve developed an interim dosing treatment which may help reduce use of illicit opioids and injectable medications among waitlisted patients.
The intervention indicated by Sigmon would save patients from regular visits to a doctor or a clinic. The opioid addiction treatment unites buprenorphine, a medicine approved by the U.S. Food and Drug Administration (FDA), and a digital dispenser that offers a single daily dose by itself. The mechanism involves alarms and locks to make sure medical adherence and prevent tampering. Additionally, it has an automatic phone-based monitoring system and random callback visits for pill counts and urine screening. This is a temporary arrangement for waitlisted patients seeking opioid therapy, letting them begin taking drugs immediately while they wait for a community-based comprehensive program.
The 12-week trial centered on establishing the effectiveness of the intervention showed favorable results. The analysis revealed that the interim buprenorphine helped waitlisted opioid-dependent participants encounter abstinence from illegal drug use. The researchers recommended the interim treatment as an effective approach to help patients avoid the potentially fatal risks of illegal opioid use while they await an intensive-care program.